Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +52.00% and -12.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?